Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Advanced or Metastatic Solid Tumors 1

Interventions

Rituximab 63Cyclophosphamide 37Brentuximab Vedotin 22Bendamustine Hydrochloride 22pembrolizumab 20fludarabine 20Gemcitabine 20Doxorubicin 20Prednisone 19ibrutinib 17Vincristine 16obinutuzumab 14Lenalidomide 13Nivolumab 10Rifampin 8parsaclisib 7duvelisib 7atezolizumab 7Vorinostat 7Dexamethasone 7Azacitidine 7spartalizumab 6loncastuximab tesirine 6MLN 8237 6venetoclax 5ixazomib 5glofitamab 5fludarabine phosphate 5durvalumab 5acalabrutinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma × TAK-981 × Clear all
NCT03648372 2024-11-19

A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System

Takeda

Phase 1/2 Terminated
109 enrolled 54 charts
LymphoidOther hematologic neoplasm

Lymphoma, Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡